A clinical trial conducted in the midst of an Ebola epidemic in the Democratic Republic of Congo (DRC) has identified two new drugs that can dramatically cut mortality from the disease, and both are being immediately offered to all patients in an effort to control the country’s worst ever outbreak.
The Pamoja Tulinde Maisha (“together save lives” in Swahili) trial began last November, in four towns stricken by the outbreak. It compared four potential treatments proposed by four different companies: ZMapp, remdesivir, mAb114, and REGN-EB3.
Preliminary data has convinced the trial’s monitoring board to stop the study and randomise all remaining patients to either mAb114 or REGN-EB3.1
Data from the first 499 patients showed that REGN-EB3 had met early stopping criteria, and mAb114 was not far behind. Among all patients who took the drugs, those treated with REGN-EB3 had a mortality rate of 29%, while those who got mAb-114 had a mortality rate of 34%.
Patients treated with ZMapp, the best known Ebola treatment candidate, which was used in the west African epidemic of 2014, had a 49% mortality rate. Those treated with the antiviral remdesivir had a 53% mortality rate.
More than 75% of those who received no treatment have died in the epidemic, which has killed nearly 1900 people out of 2831 confirmed cases.
Researchers believe they can improve outcomes further in patients who are reached early in the course of infection. Among such patients, mortality rates were 6% with REGN-EB3, 11% with mAb114, 24% with ZMapp, and 33% with remdesivir.
Both REGN-EB3 and mAb114, like ZMapp, are monoclonal antibodies, proteins that bind to other proteins on the outer shell of the Ebola virus, which it uses to attach itself to human cells.
Regeneron Pharmaceuticals made REGN-EB3, a cocktail of three such proteins, using antibodies from “humanised” mice infected with Ebola.
The US National Institute of Allergy and Infectious Diseases created mAb114 using antibodies isolated from the blood of a survivor of a 1995 outbreak in DRC. It will be developed by Ridgeback Therapeutics.
“From now on, we will no longer say that Ebola is incurable,” said Jean-Jacques Muyembe-Tamfum, director of the DRC’s Institut National de Recherche Biomédicale, which oversaw the trial. Full results are expected by early October and will appear in a peer reviewed journal soon thereafter.
Muyembe, who was part of the team that discovered the Ebola virus 43 years ago, and who in 1995 became the first doctor to harvest antibodies from survivors, told a press conference that the news of effective treatments would reinvigorate the campaign to end the current outbreak, which has struggled against deep local suspicion in a region plagued by insecurity.
“People think that if you enter a treatment centre, you’ll leave in a coffin,” said Muyembe. But with such high survival rates in the newly infected, he said, “We have a great message: a treatment centre is a place where you can recover and that you leave alive.”
The Latest on: Ebola
via Google News
The Latest on: Ebola
- Ebola survivors may be at increased risk of death, study suggestson September 6, 2019 at 7:37 am
An Ebola survivor, who works as a caregiver, holds an infant near a treatment center in Butembo, DRC. Photo by: REUTERS / Baz Ratner MANILA — A new study is prompting efforts to further understand the ...
- Ebola's economic effectson September 6, 2019 at 6:23 am
While the world's media may well have moved on to new stories, the 2014 Ebola outbreak in West Africa, which was one of the most devastating in history, continues to have a significant impact on ...
- Women and Children at Greater Risk of Ebola - WHOon September 6, 2019 at 4:50 am
According to data from the World Health Organisation, women and girls aged 11 and older have contracted Ebola at a higher rate than men and boys in the same age range and young children - five and ...
- Commentary: Ebola is raging again — and the U.S. is not readyon September 5, 2019 at 11:38 pm
Five years ago, the Ebola virus broke through inadequate public health systems in West Africa and spread throughout the world. America was lucky. Only a few cases traveled here, but the U.S.
- Congo-Kinshasa: Briefing - Why Women and Children Are At Greatest Risk As Ebola Continues to Spread in Congoon September 5, 2019 at 9:45 pm
As schools reopen this week in the Democratic Republic of Congo, the situation is worrisome for some two million children and their families in the Ebola outbreak zones in the east of the country.
- Longer-Term Effects of Ebola Contribute to Death in Survivorson September 5, 2019 at 2:18 pm
Longer-term effects of Ebola infection, such as renal failure, contributed to many subsequent deaths among survivors of the 2013-2016 Ebola outbreak in West Africa, researchers found. In the nation of ...
- Ebola survivors face increased risk of deathon September 5, 2019 at 8:39 am
The overall death rate of the Ebola outbreak in West Africa may have been underestimated, with new research finding survivors could have a five times higher death rate after leaving the hospital than ...
- Mortality rates in Ebola survivors after hospital discharge could be 5 times higher compared with the general populationon September 5, 2019 at 12:35 am
First study of its kind suggests Ebola survivors may be at increased risk of death in the first year after hospital discharge, particularly those who spent longer in hospital. In the first year ...
- Ebola survivors at higher risk of dying, even after recoveryon September 4, 2019 at 3:58 pm
LONDON — A study that tracked over 1,000 Ebola survivors found they had a higher than usual chance of dying in the year after their recovery. Some health officials said the results suggest more should ...
- Ebola survivors face kidney problems and risk of premature deathon September 4, 2019 at 3:55 pm
LONDON (Reuters) - People who survive Ebola virus infection face a dramatically higher risk of dying - probably from severe kidney damage - within a year of leaving hospital, according to a study of ...
via Bing News